Has James Deering, MD received payments from drug or device companies?

Yes. Drug and device makers reported $93,078 in general payments to James Deering, MD across 537 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Deering, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Deering, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Deering, MD

Pain Medicine · Charlotte, NCNPI 1043576051

Payments from drug & device makers

$93,078in general payments, 2019–2025

Across 537 payments — averaging $173.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$57K
Nevro Corp.$12K
Medtronic$10K
Saluda Medical Americas, Inc.$10K
Relievant Medsystems, Inc.$1K
Abbott$657
plus $2K from 21 others

$150in research payments, 2019–2025

Across 1 payment — averaging $150.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Saluda Medical Americas, Inc.$150

What the payments were for

Consulting fees$5,4006%
Speaking & faculty fees$46,23850%
Grants$7,5008%
Travel & lodging$12,58514%
Food & beverage$21,35523%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	241	$56,698
Nevro Corp.	117	$12,312
Medtronic(2 entities)	45	$10,333
Saluda Medical Americas, Inc.	48	$10,028
Relievant Medsystems, Inc.	15	$1,169
Abbott	5	$657
Painteq LLC	9	$478
Vertos Medical, Inc.	6	$252
Biodelivery Sciences International, Inc.	12	$183
SPR Therapeutics, Inc	4	$180
Nalu Medical, Inc.	7	$119
Pacira Therapeutics, Inc.	1	$105
Almatica Pharma LLC	4	$82
Biohaven Pharmaceuticals, Inc.	4	$77
Convatec Inc.	1	$63
Pfizer	2	$38
Avanos Medical	2	$38
Collegium Pharmaceutical, Inc.	2	$36
AbbVie	2	$34
Vertiflex, Inc.	1	$34
Globus Medical	1	$34
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$32
Scilex Pharmaceuticals Inc.	2	$30
Acelrx Pharmaceuticals, Inc.	1	$19
Redhill Biopharma Inc.	1	$19
Baudax Bio Inc.	1	$14
Covidien LP	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

WaveWriter Alpha Prime 16$32,752
SYNCHROMED$7,500
Evoke$6,400
Omnia$5,119
Senza Spinal Cord Stimulation System$3,526
Evoke SCS$3,030
Intracept$1,821
WAVEWRITER ALPHA$1,270
INCEPTIV$889
Senza$828
ETERNA$645
RESTORE$509
GENERAL - THERAPIES$405
INTELLIS$276
GENERAL PAIN MANAGEMENT$266
SPECTRA WAVEWRITER$253
PAINTEQ$183
INTELLIS ADAPTIVESTIM$137
Zilretta$105

How this compares

$93,078 in reported general payments places this provider in the 90th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina →

Medicare billing

Part B allowed, 2024

$125,216

Medicare patients

275

Services billed

1,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	29	$1,641
Celecoxib	30	$1,378
Gabapentin	90	$1,034
Diclofenac Sodium	20	$663
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	57	$590
Tramadol Hcl	64	$478
Pregabalin	24	$342
Cyclobenzaprine Hcl	15	$202
Meloxicam	32	$91
Tizanidine Hcl	15	$90
Cephalexin	25	$57

Paid to pharmacies, not to this prescriber.

Other pain medicine in Charlotte

Jacob WangCharlotte$162K
Aashish KumarCharlotte$160K
Ankur ManvarCharlotte$33K
Russell DavenportCharlotte$26K
Gerald AronoffCharlotte$17K
Raza KhanCharlotte$12K
Adewunmi AkandeCharlotte$12K
Alexander RothkrugCharlotte$10K
Cameron CunninghamCharlotte$8K
Leonardo KapuralWinston Salem$4.1M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →